PMID- 29488406
OWN - NLM
STAT- MEDLINE
DCOM- 20190118
LR  - 20190722
IS  - 1744-7593 (Electronic)
IS  - 1742-5247 (Linking)
VI  - 15
IP  - 5
DP  - 2018 May
TI  - Intraperitoneal chemotherapy for ovarian cancer using sustained-release 
      implantable devices.
PG  - 481-494
LID - 10.1080/17425247.2018.1446938 [doi]
AB  - INTRODUCTION: Epithelial ovarian cancer (EOC) remains to be the most lethal of 
      all gynecological malignancies mainly due to its asymptomatic nature. The late 
      stages are manifested with predominant metastases confined to the peritoneal 
      cavity. Although there has been a substantial progress in the treatment avenue 
      with different therapeutic interventions, the overall survival rate of patients 
      remain poor due to relapse and drug resistance. AREAS COVERED: The 
      pharmacokinetic advantages offered by intraperitoneal (IP) chemotherapy due to 
      peritoneal-plasma barrier can be potentially exploited for EOC relapse treatment. 
      The ability to retain high concentrations of chemo-drugs with high AUC 
      peritoneum/plasma for prolonged durations in the peritoneal cavity can be 
      utilized effectively through the clinical adoption of drug delivery systems 
      (DDSs) which obviates the need for indwelling catheters. The metronomic dosing 
      strategy could enhance anti-tumor efficacy with a continuous, low dose of 
      chemo-drugs providing minimal systemic toxicity. EXPERT OPINION: The development 
      of a feasible, non-catheter based, IP DDS, retaining the peritoneal-drug levels, 
      with less systemic levels could offer significant survival advantages as a 
      patient-compliant therapeutic strategy. Suturable-implantable devices based on 
      metronomic dosing, eluting drug in a sustained manner at low doses, could be 
      implanted surgically post-debulking for treatment of refractory EOC patients.
FAU - Padmakumar, Smrithi
AU  - Padmakumar S
AD  - a Department of Pharmaceutical Sciences, School of Pharmacy , Northeastern 
      University , Boston , MA , USA.
AD  - b Centre for Nanosciences and Molecular Medicine , Amrita Institute of Medical 
      Sciences, Amrita Vishwa Vidyapeetham , Kochi , India.
FAU - Parayath, Neha
AU  - Parayath N
AD  - a Department of Pharmaceutical Sciences, School of Pharmacy , Northeastern 
      University , Boston , MA , USA.
FAU - Leslie, Fraser
AU  - Leslie F
AD  - a Department of Pharmaceutical Sciences, School of Pharmacy , Northeastern 
      University , Boston , MA , USA.
FAU - Nair, Shantikumar V
AU  - Nair SV
AD  - b Centre for Nanosciences and Molecular Medicine , Amrita Institute of Medical 
      Sciences, Amrita Vishwa Vidyapeetham , Kochi , India.
FAU - Menon, Deepthy
AU  - Menon D
AD  - b Centre for Nanosciences and Molecular Medicine , Amrita Institute of Medical 
      Sciences, Amrita Vishwa Vidyapeetham , Kochi , India.
FAU - Amiji, Mansoor M
AU  - Amiji MM
AD  - a Department of Pharmaceutical Sciences, School of Pharmacy , Northeastern 
      University , Boston , MA , USA.
LA  - eng
GR  - R56 CA198492/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180306
PL  - England
TA  - Expert Opin Drug Deliv
JT  - Expert opinion on drug delivery
JID - 101228421
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Implants)
SB  - IM
MH  - Antineoplastic Agents/*administration & dosage
MH  - Delayed-Action Preparations/*administration & dosage
MH  - *Drug Delivery Systems
MH  - Drug Implants
MH  - Female
MH  - Humans
MH  - Injections, Intraperitoneal
MH  - Neoplasm Recurrence, Local
MH  - Ovarian Neoplasms/*drug therapy
OTO - NOTNLM
OT  - Intraperitoneal therapy
OT  - localized drug delivery
OT  - metronomic dosing
OT  - ovarian cancer
OT  - peritoneum
OT  - sustained release
EDAT- 2018/03/01 06:00
MHDA- 2019/01/19 06:00
CRDT- 2018/03/01 06:00
PHST- 2018/03/01 06:00 [pubmed]
PHST- 2019/01/19 06:00 [medline]
PHST- 2018/03/01 06:00 [entrez]
AID - 10.1080/17425247.2018.1446938 [doi]
PST - ppublish
SO  - Expert Opin Drug Deliv. 2018 May;15(5):481-494. doi: 
      10.1080/17425247.2018.1446938. Epub 2018 Mar 6.